154 related articles for article (PubMed ID: 35259923)
1.
Yang C; Zhang Q; Tang X; Wang B; Guan M; Tang G; Wu Z
Epigenomics; 2022 Apr; 14(7):391-403. PubMed ID: 35259923
[TBL] [Abstract][Full Text] [Related]
2. Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
Yang JJ; Chen H; Zheng XQ; Li HY; Wu JB; Tang LY; Gao SM
Asian Pac J Cancer Prev; 2015; 16(6):2219-25. PubMed ID: 25824741
[TBL] [Abstract][Full Text] [Related]
3. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
[TBL] [Abstract][Full Text] [Related]
4. Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
Kim T; Ahn JS; Son MH; Novitzky-Basso I; Yi SY; Ahn SY; Jung SH; Yang DH; Lee JJ; Choi SH; Lee JY; Moon JH; Sohn SK; Kim HJ; Zhang Z; Kim DDH
Leuk Res; 2022 Jul; 118():106858. PubMed ID: 35609360
[TBL] [Abstract][Full Text] [Related]
5. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
Zhang SJ; Abdel-Wahab O
Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
[TBL] [Abstract][Full Text] [Related]
6. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
Li B; Mascarenhas JO; Rampal RK
Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
[TBL] [Abstract][Full Text] [Related]
7. Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms.
Elbracht M; Meyer R; Kricheldorf K; Gezer D; Eggermann T; Betz B; Kurth I; Teichmann LL; Brümmendorf TH; Germing U; Isfort S; Koschmieder S
Blood Adv; 2021 Sep; 5(17):3373-3376. PubMed ID: 34477817
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
9. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
10. Investigation of DNA damage response and apoptotic gene methylation pattern in sporadic breast tumors using high throughput quantitative DNA methylation analysis technology.
Pal R; Srivastava N; Chopra R; Gochhait S; Gupta P; Prakash N; Agarwal G; Bamezai RN
Mol Cancer; 2010 Nov; 9():303. PubMed ID: 21092294
[TBL] [Abstract][Full Text] [Related]
11. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.
Ding Y; Harada Y; Imagawa J; Kimura A; Harada H
Blood; 2009 Dec; 114(25):5201-5. PubMed ID: 19850737
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue.
Lobanova OE; Rossokha ZI; Medvedieva NL; Cheshuk VE; Vereshchako RI; Vershyhora VO; Fishchuk LY; Zakhartseva LM; Gorovenko NG
Exp Oncol; 2021 Mar; 43(1):56-60. PubMed ID: 33785722
[TBL] [Abstract][Full Text] [Related]
14. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
15. MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.
Grabek J; Straube J; Bywater M; Lane SW
Cells; 2020 Aug; 9(8):. PubMed ID: 32823933
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics in Myeloproliferative Neoplasms.
McPherson S; McMullin MF; Mills K
J Cell Mol Med; 2017 Sep; 21(9):1660-1667. PubMed ID: 28677265
[TBL] [Abstract][Full Text] [Related]
18. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.
Pérez C; Pascual M; Martín-Subero JI; Bellosillo B; Segura V; Delabesse E; Álvarez S; Larrayoz MJ; Rifón J; Cigudosa JC; Besses C; Calasanz MJ; Cross NC; Prósper F; Agirre X
Haematologica; 2013 Sep; 98(9):1414-20. PubMed ID: 23716560
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
20. Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms.
Chim CS; Wan TS; Wong KY; Fung TK; Drexler HG; Wong KF
J Transl Med; 2011 Nov; 9():197. PubMed ID: 22082000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
